5-HT 1B/1D RECEPTOR AGONISTS FOR THE TREATMENT OF HEADACHE RESULTING FROM ADMINISTERING AN ENDOTHELIN RECEPTOR ANTAGONIST

Details for Australian Patent Application No. 2003274307 (hide)

Owner ASTRAZENECA AB

Inventors MORRIS, Clive, Dylan; CURWEN, Jon, Owen; HUGHES, Andrew, Mark; JOHNSTONE, Donna

Pub. Number AU-A-2003274307

PCT Number PCT/GB03/04338

PCT Pub. Number WO2004/032922

Priority 0223367.4 09.10.02 GB

Filing date 6 October 2003

Wipo publication date 4 May 2004

International Classifications

A61K 031/4045

A61K 031/422 - not condensed and containing further heterocyclic rings

A61K 031/404

A61K 031/405

A61K 031/445 - Non-condensed piperidines, e.g. piperocaine

A61K 031/216

A61K 031/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine

A61K 031/192

A61K 031/18 - Sulfonamides

A61K 031/635

A61K 031/506 - not condensed and containing further heterocyclic rings

A61P 025/06 Drugs for disorders of the nervous system

Event Publications

12 February 2004 Complete Application Filed

  Priority application(s): 0223367.4 09.10.02 GB

3 June 2004 Application Open to Public Inspection

  Published as AU-A-2003274307

14 July 2005 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003274308-FREQUENCY STABILIZED LASER SYSTEM COMPRISING PHASE MODULATION OF BACKSCATTERED LIGHT

2003274306-Combination therapy with gemcitabine and ZD6126